South Texas Accelerated Research Therapeutics

San Antonio, Texas TX 78229

5 studies enrolling now · 76 studies all time

What they study most

Acute Myeloid Leukemia, Adrenal Gland Tumors, Advanced Cancer, Advanced MTAP-null Solid Tumors, Advanced Malignancies, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Tumors, Advanced or Metastatic Biliary Cancer, Appendiceal Adenocarcinoma, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic

Studies at this site

• IDOV-Immune for Advanced Solid Tumors — Recruiting now
• A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of GEN1106 in Participants With Solid Tumors — Recruiting now
• Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion — Recruiting now
• Clinical Trial of PM54 in Advanced Solid Tumors Patients. — Recruiting now
• Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer — Running, not enrolling
• Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors — Completed
• A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors — Completed
• A Study to Evaluate INCB177054 in Participants With Select Advanced or Metastatic Solid Tumors — Running, not enrolling
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors — Running, not enrolling
• A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101) — Running, not enrolling
• A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors — Stopped early
• Study of INCA 0186 in Subjects With Advanced Solid Tumors — Stopped early
• A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors — Completed
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors — Completed
• A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies — Stopped early
• A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b — Completed
• Oral Administration of STC-15 in Subjects With Advanced Malignancies — Completed
• LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors — Completed
• A Study of SGN-STNV in Advanced Solid Tumors — Stopped early
• FPA150 in Patients With Advanced Solid Tumors — Stopped early
• A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors — Completed
• The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. — Stopped early
• Study of SRF617 in Patients With Advanced Solid Tumors — Completed
• A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors — Completed
• A Phase I Study of MSB2311 in Advanced Solid Tumors — Completed
• A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors — Stopped early
• Study of ASN003 in Subjects With Advanced Solid Tumors — Stopped early
• A Study of SGN-CD228A in Advanced Solid Tumors — Stopped early
• INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors — Completed
• Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer — Completed
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) — Stopped early
• A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread — Completed
• Study of CPI-100 in Patients With Advanced Tumors — Completed
• A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors — Stopped early
• A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers — Completed
• Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors — Completed
• A Study of SY-1365 in Adult Patients With Advanced Solid Tumors — Stopped early
• Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors — Status unconfirmed
• A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function — Completed
• Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors — Completed
• A Study of ARRY-438162 (MEK162) in Patients With Advanced Cancer — Completed
• A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors — Completed
• A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors — Completed
• A Study of ASN007 in Patients With Advanced Solid Tumors — Completed
• A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors — Stopped early
• A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors — Completed
• LZM009 to Treat Patients With Advanced Solid Tumors — Completed
• A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas — Completed
• Phase 1 of EC1169 In Patients With Recurrent MCRPC — Completed